

APC Anti-Mouse CD273 Monoclonal Antibody



天津三箭生物技术股份有限公司
Tianjin Sungene Biotech Co., Ltd.
精准 高效 稳定 Precision Efficient Stable

Catalog Number	Vial Size
M12731-11A	25 µg
M12731-11C	100 µg

Market | 400-621-0003
marketing@sungenebiotech.com

Support | 022-66211636-8024
techsupport@sungenebiotech.com

Web | www.sungenebiotech.com

Important Note: Centrifuge before opening to ensure complete recovery of vial contents.
This product is guaranteed up to one year from purchase.

Purified Antibody Characterization

Clone	Isotype	Reactivity
TY25	Rat IgG2a	Mouse

Description

CD273 is also called programmed death ligand 2 (PD-L2), also known as B7-DC. It has recently been clustered as CD273. This ligand is a 42 kD member of the immunoglobulin receptor superfamily expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 is primarily expressed by sub-populations of dendritic cells, monocytes and macrophages. Although B7-DC has structural and sequence similarities to the B7 family, it does not bind CD28/CTLA-4, but binds PD-1. The interactions between PD-1 and B7-DC/PD-L2 have been reported to be involved in costimulation or suppression of T cell proliferation depending on state of cellular activation. TY25 is a useful tool to study the exact function of B7-DC/PD-L2 in APC/T cell interaction and to characterize the expression pattern of this molecule in mouse.

Product Information

Conjugation: APC

Formulation: PBS pH 7.2, 0.09% NaN₃, 0.2% BSA

Concentration: 0.2 mg/ml

Storage: Keep as concentrated solution. Store at 4°C and protected from prolonged exposure to light. **Do not freeze.**

Application: Recommended Application: FC

Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis (The amount of the reagent is suggested to be used ≤ 1.0 µg /10⁶ cells in 100 µl). Since applications vary, the appropriate dilutions must be determined for individual use.

References

- [1] Yamazaki T, et al. 2002. J. Immunol. 169:5538. (FC, IP, WB)
- [2] Ansari MJI, et al. 2003. J. Exp. Med. 198:63. (Block)
- [3] Salama AD, et al. 2003. J. Exp. Med. 198:71. (IHC)
- [4] Matsumoto K, et al. 2004. J. Immunol. 172:2530. (FC, Block)
- [5] Yamazaki T, et al. 2005. J. Immunol. 175:1586. (Block)

For Research Use Only.